Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

PURPOSE: To evaluate the prognostic factors associated with survival in patients treated with neoadjuvant treatment [chemoradiotherapy (CRT) or chemotherapy] followed by surgery (CRTS) in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). METHODS: A retrospective study was conducted of 118 patients diagnosed with stage T1-T3N2M0 NSCLC and treated with CRTS at 14 hospitals in Spain between January 2005 and December 2014. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was performed. RESULTS: Surgery consisted of lobectomy (74.5% of cases), pneumectomy (17.8%), or bilobectomy (7.6%). Neoadjuvant treatment was CRT in 62 patients (52.5%) and chemotherapy alone in 56 patients (47.5%). Median follow-up was 42.5 months (5-128 months). 5-year OS and PFS were 51.1% and 49.4%, respectively. The following variables were independently associated with worse OS and PFS: pneumonectomy (vs. lobectomy); advanced pathologic T stage (pT3 vs. pT0-pT2); and presence of persistent N2 disease (vs. ypN0-1) in the surgical specimen. CONCLUSIONS: In this sample of patients with stage IIIA-N2 NSCLC treated with CRTS, 5-year survival (both OS and PFS) was approximately 50%. After CRTS, the patients with the best prognosis were those whose primary tumour and/or mediastinal nodal metastases were downstaged after induction therapy and those who underwent lobectomy. These findings provide further support for neoadjuvant therapy followed by surgery in selected patients.

Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).

OBJECTIVES: The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively debated in oncology. To evaluate the value of surgery in this patient population, we conducted a multi-institutional retrospective study comparing neoadjuvant chemoradiotherapy or chemotherapy plus surgery (CRTS) to definitive chemoradiotherapy (dCRT). MATERIAL AND METHODS: A total of 247 patients with potentially resectable stage T1-T3N2M0 NSCLC treated with either CRTS or dCRT between January 2005 and December 2014 at 15 hospitals in Spain were identified. A centralized review was performed to ensure resectability. A propensity score matched analysis was carried out to balance patient and tumor characteristics (n = 78 per group). RESULTS: Of the 247 patients, 118 were treated with CRTS and 129 with dCRT. In the CRTS group, 62 patients (52.5%) received neoadjuvant CRT and 56 (47.4%) neoadjuvant chemotherapy. Surgery consisted of either lobectomy (97 patients; 82.2%) or pneumonectomy (21 patients; 17.8%). In the matched samples, median overall survival (OS; 56 vs 29 months, log-rank p = .002) and progression-free survival (PFS; 46 vs 15 months, log-rank p < 0.001) were significantly higher in the CRTS group. This survival advantage for CRTS was maintained in the subset comparison between the lobectomy subgroup versus dCRT (OS: 57 vs 29 months, p < 0.001; PFS: 46 vs 15 months, p < 0.001), but not in the comparison between the pneumonectomy subgroup and dCRT. CONCLUSION: The findings reported here indicate that neoadjuvant chemotherapy or chemoradiotherapy followed by surgery (preferably lobectomy) yields better OS and PFS than definitive chemoradiotherapy in patients with resectable stage IIIA-N2 NSCLC.

Recent developments in radiotherapy for small-cell lung cancer: a review by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Small-cell lung cancer (SCLC) accounts for 13% of all lung tumours. The standard treatment in patients with limited-stage disease is radiotherapy combined with chemotherapy. In extensive SCLC, the importance of consolidation thoracic radiotherapy in patients with a good treatment response has become increasingly recognized. In both limited and extensive disease, prophylactic cranial irradiation is recommended in patients who respond to treatment. New therapeutic approaches such as immunotherapy are being increasingly incorporated into the treatment of SCLC, although more slowly than in non-small cell lung cancer (NSCLC). Diverse radiation dose and fractionation schemes, administered in varying combinations with these new drugs, are being investigated. In the present study we review and update the role of radiotherapy in the treatment of SCLC. We also discuss the main clinical trials currently underway in order to identify future trends.

Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

In recent years, major advances in our understanding of the molecular biology of lung cancer, together with significant improvements in radiotherapy technologies, have revolutionized the treatment of non-small cell lung cancer (NSCLC). This has led to the development of new therapies that target molecular mutations specific to each tumor type, acting on the cell surface antigens or intracellular signaling pathways, or directly affecting cell survival. At the same time, ablative dose radiotherapy can be delivered safely in the context of metastatic disease. In this article, the GOECP/SEOR (Oncological Group for Study of Lung Cancer/Spanish Society of Radiation Oncology) reviews the role of new targeted therapies used in combination with radiotherapy in patients with locally advanced (stage III) NSCLC and in patients with advanced, metastatic (stage IV) NSCLC.

Etiología de la neumonía adquirida en la comunidad en un hospital de cuarto nivel en Bogotá: estudio descriptivo de un registro institucional durante los años 2007 a 2012 / Etiology of community acquired pneumonia in a fourth level attention hospital in Bogotá: Descriptive study of an institutional record during 2007 to 2012

Introducción: La neumonía adquirida en la comunidad (NAC) puede ser causada por diferentes gérmenes. En Latinoamérica la principal etiología es Streptococcus pneumoniae , aislado en aproximadamente el 35-40% de los casos. Objetivos: Describir las características de los pacientes hospitalizados con diagnóstico de NAC durante 6 años en la Fundación Santa Fe de Bogotá, los principales agentes etiológicos y el patrón de susceptibilidad antibiótica en los microorganismos más importantes. Materiales y métodos: Estudio descriptivo retrospectivo que incluyó a todos los pacientes mayores de 16 años hospitalizados con diagnóstico de NAC. Se revisaron variables demográficas y clínicas, presencia de pruebas diagnósticas para determinar etiología y los microorganismos aislados. Resultados: Se aisló un germen en 130 pacientes, siendo los más frecuentes Streptococcus pneumoniae , Haemophilus influenzae y Staphylococcus aureus . Encontramos mayor frecuencia de microorganismos atípicos en menores de 65 años y en pacientes sin comorbilidades, y de enterobacterias en mayores de 65 años y en pacientes con comorbilidades. Discusión: Los principales gérmenes aislados son similares a los reportados en otras series. Llama la atención la frecuencia de Staphylococcus aureus y la presencia de SAMR. Es importante conocer la etiología local para adaptar las guías de manejo de acuerdo a los gérmenes encontrados, la susceptibilidad a los antibióticos y la disponibilidad de recursos.

Introduction: Community acquired pneumonia (CAP) can be caused by different microorganisms. In Latin America the main cause is Streptococcus pneumoniae isolated in about 35-40% of cases. Objectives: To describe the characteristics of patients admitted with diagnosis of CAP at Fundación Santa Fe de Bogotá during a 6 years period, the etiological agents isolated and the pattern of antibiotic susceptibility in the most frequent microorganisms. Materials and methods: Retrospective descriptive study; all patients older than 16 years admitted with diagnosis of CAP were included. Demographic and clinical variables, diagnostic tests to evaluate etiology and the microorganisms isolated were reviewed. Results: At least one microorganism was isolated in 130 patients, being the most common Streptococcus pneumoniae , Haemophilus influenzae and Staphylococcus aureus . We found higher frequency of atypical microorganisms in patients under 65 years and without comorbidities, while enteric gram-negative rods were more frequent in patients with comorbidities or older than 65 years. Discussion: Our most common etiologies are similar to those reported in other series. Special attention is drawn to Staphylococcus aureus as one of the major etiologies and the presence of MRSA. It is important to know the local etiology to adjust guidelines according to the isolated microorganisms, antibiotics susceptibility and availability of resources.

Vasculitis in hairy cell leukemia: rapid response to interferon alpha.

A patient with hairy cell leukemia (HCL) and vasculitis was treated only with interferon alpha-2b. A good, rapid response was obtained without using corticosteroids or immunosuppressors. Interferon may prove to be useful for the systemic therapy of patients with vasculitis associated with HCL.